EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027

EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027

The European market for pain management drugs is a major contributor towards the global pain management drugs market growth due to the presence of a large number of patient population base suffering pain in the region. High demand for pain relievers’ medications in Europe has led to the emergence of numerous drugs manufacturing companies. The Europe market is proliferating at 3.96% CAGR through 2019-2027.

EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027

Europe Pain Management Drugs Market by Drug Class (Nsaids, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Non-narcotic Analgesics), Market by (Indication, Arthriticpain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-operative Pain, Migraine, Fibromyalgia) & by Geography.

Request free sample

The European market for pain management drugs is a major contributor towards the global pain management drugs market growth due to the presence of a large number of patient population base suffering pain in the region. High demand for pain relievers’ medications in Europe has led to the emergence of numerous drugs manufacturing companies. The Europe market is proliferating at 3.96% CAGR through 2019-2027.

The pain management market of the United Kingdom, Germany, France, Italy, Spain & the collective countries from the Rest of Europe influence the global market growth. The multiple cases of opioid dependence are anticipated to augment the demand for opioid drugs in Germany. However, the rising concern of the opioid epidemic across the world has seriously impacted the growth of opioid drug market in Germany. Due to the moderate death toll in the United Kingdom due to the ineffective dosage of certain pain-relieving medications, their respective dosages are limited to a shorter period. This has lowered the preference of such drugs by the patient. This has augmented the demand for effective pain therapy in the country.

The major market players in Europe are Daiichi Sankyo, Inc., Purdue Pharma L.P., Acura Pharmaceuticals, Inc., Novartis, Egalet Corp., Eli Lilly and Company, Insys Therapeutics, Inc., GlaxoSmithKline, Abbott Laboratories, Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Pfizer, Inc., Merck & Co., Inc. and Cipher Pharmaceuticals Inc.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • OPIOIDS MARKET HOLDS THE LARGEST MARKET SHARE IN TERMS OF DRUG CLASS
      • CANCER PAIN INDICATION IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • GROWTH IN THE INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
      • THE RISE IN AWARENESS REGARDING THE SIDE-EFFECTS OF PAIN MEDICATION
      • RISE IN GERIATRIC POPULATION
    • MARKET RESTRAINTS
      • ACCESSIBILITY OF ALTERNATIVE THERAPIES
      • INCREASE IN DRUG MISTREATMENT
    • MARKET OPPORTUNITIES
      • TECHNOLOGICAL ADVANCEMENT
      • GROWTH POTENTIAL IN UNTAPPED ECONOMIES
    • MARKET CHALLENGES
      • PATENT EXPIRATION
  1. MARKET BY DRUG CLASS
    • NSAIDS
    • ANESTHETICS
    • ANTICONVULSANTS
    • ANTI-MIGRAINE AGENTS
    • ANTIDEPRESSANTS
    • OPIOIDS
    • NON-NARCOTIC ANALGESICS
  2. MARKET BY INDICATION
    • ARTHRITIC PAIN
    • NEUROPATHIC PAIN
    • CANCER PAIN
    • CHRONIC BACK PAIN
    • POST-OPERATIVE PAIN
    • MIGRAINE
    • FIBROMYALGIA
  3. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF COMPETITIVE RIVALRY
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
    • VALUE CHAIN ANALYSIS
    • VENDOR LANDSCAPE
  4. GEOGRAPHICAL ANALYSIS
    • EUROPE
      • GERMANY
      • FRANCE
      • THE UNITED KINGDOM
      • ITALY
      • SPAIN
      • REST OF EUROPE
  1. COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS
    • COMPANY PROFILES
      • ABBOTT LABORATORIES
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ACURA PHARMACEUTICALS, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • CIPHER PHARMACEUTICALS INC.
        • COMPANY PROFILES
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • DAIICHI SANKYO, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • EGALET CORP.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • ELI LILLY AND COMPANY
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GLAXOSMITHKLINE
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • HIKMA PHARMACEUTICALS PLC
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • JOHNSON & JOHNSON
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • LUPIN LTD.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • PFIZER, INC.
        • COMPANY PROFILES
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PURDUE PHARMA L.P.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES
      • MERCK & CO., INC.
        • COMPANY PROFILES
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • NOVARTIS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • INSYS THERAPEUTICS, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • STRATEGIC INITIATIVES

TABLE LIST

TABLE  1      EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

TABLE  2      EUROPE PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  3      EUROPE NSAIDS MARKET 2019-2027 ($ MILLION)

TABLE  4      EUROPE ANESTHETICS MARKET 2019-2027 ($ MILLION)

TABLE  5      EUROPE ANTICONVULSANTS MARKET 2019-2027 ($ MILLION)

TABLE  6      EUROPE ANTI-MIGRAINE AGENTS MARKET 2019-2027 ($ MILLION)

TABLE  7      EUROPE ANTIDEPRESSANTS MARKET 2019-2027 ($ MILLION)

TABLE  8      EUROPE OPIOIDS MARKET 2019-2027 ($ MILLION)

TABLE  9      EUROPE NON-NARCOTIC ANALGESICS MARKET 2019-2027 ($ MILLION)

TABLE  10    EUROPE PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)

TABLE  11    EUROPE ARTHRITIC PAIN MARKET 2019-2027 ($ MILLION)

TABLE  12    EUROPE NEUROPATHIC PAIN MARKET 2019-2027 ($ MILLION)

TABLE  13    EUROPE CANCER PAIN MARKET 2019-2027 ($ MILLION)

TABLE  14    EUROPE CHRONIC BACK PAIN MARKET 2019-2027 ($ MILLION)

TABLE  15    EUROPE POST-OPERATIVE PAIN MARKET 2019-2027 ($ MILLION)

TABLE  16    EUROPE MIGRAINE MARKET 2019-2027 ($ MILLION)

TABLE  17    EUROPE FIBROMYALGIA MARKET 2019-2027 ($ MILLION)

TABLE  18    EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

TABLE  19    EUROPE PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  20    GERMANY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  21    GERMANY PAIN MANAGEMENT DRUGS MARKET BY INDICATION  2019-2027 ($ MILLION)

TABLE  22    FRANCE PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  23    FRANCE PAIN MANAGEMENT DRUGS MARKET BY INDICATION  2019-2027 ($ MILLION)

TABLE  24    THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  25    THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY INDICATION  2019-2027 ($ MILLION)

TABLE  26    ITALY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  27    ITALY PAIN MANAGEMENT DRUGS MARKET BY INDICATION  2019-2027 ($ MILLION)

TABLE  28    SPAIN PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  29    SPAIN PAIN MANAGEMENT DRUGS MARKET BY INDICATION  2019-2027 ($ MILLION)

FIGURE LIST 

FIGURE  1    EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  2    EUROPE PAIN MANAGEMENT DRUGS MARKET SHARE BY DRUG CLASS 2018 & 2027 (%)

FIGURE  3    EUROPE PAIN MANAGEMENT DRUGS MARKET BY NSAIDS 2019-2027 ($ MILLION)

FIGURE  4    EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANESTHETICS 2019-2027 ($ MILLION)

FIGURE  5    EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTICONVULSANTS 2019-2027 ($ MILLION)

FIGURE  6    EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTI-MIGRAINE AGENTS 2019-2027 ($ MILLION)

FIGURE  7    EUROPE PAIN MANAGEMENT DRUGS MARKET BY ANTIDEPRESSANTS 2019-2027 ($ MILLION)

FIGURE  8    EUROPE PAIN MANAGEMENT DRUGS MARKET BY OPIOIDS 2019-2027 ($ MILLION)

FIGURE  9    EUROPE PAIN MANAGEMENT DRUGS MARKET BY NON-NARCOTIC ANALGESICS 2019-2027 ($ MILLION)

FIGURE  10  EUROPE PAIN MANAGEMENT DRUGS MARKET SHARE BY INDICATION 2018 & 2027 (%)

FIGURE  11  EUROPE PAIN MANAGEMENT DRUGS MARKET BY ARTHRITIC PAIN 2019-2027 ($ MILLION)

FIGURE  12  EUROPE PAIN MANAGEMENT DRUGS MARKET BY NEUROPATHIC PAIN 2019-2027 ($ MILLION)

FIGURE  13  EUROPE PAIN MANAGEMENT DRUGS MARKET BY CANCER PAIN 2019-2027 ($ MILLION)

FIGURE  14  EUROPE PAIN MANAGEMENT DRUGS MARKET BY CHRONIC BACK PAIN 2019-2027 ($ MILLION)

FIGURE  15  EUROPE PAIN MANAGEMENT DRUGS MARKET BY POST-OPERATIVE PAIN 2019-2027 ($ MILLION)

FIGURE  16  EUROPE PAIN MANAGEMENT DRUGS MARKET BY MIGRAINE 2019-2027 ($ MILLION)

FIGURE  17  EUROPE PAIN MANAGEMENT DRUGS MARKET BY FIBROMYALGIA 2019-2027 ($ MILLION)

FIGURE  18  PORTER’S FIVE FORCE MODEL

FIGURE  19  EUROPE PAIN MANAGEMENT DRUGS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

FIGURE  20  GERMANY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  21  FRANCE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  22  THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  23  ITALY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  24  SPAIN PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  25  REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  26  PAIN MANAGEMENT MARKET SHARE ANALYSIS 2017 (%)

  1. GEOGRAPHICAL ANALYSIS
    • EUROPE
      • GERMANY
      • FRANCE
      • THE UNITED KINGDOM
      • ITALY
      • SPAIN
      • REST OF EUROPE
  1. MARKET BY DRUG CLASS
    • NSAIDS
    • ANESTHETICS
    • ANTICONVULSANTS
    • ANTI-MIGRAINE AGENTS
    • ANTIDEPRESSANTS
    • OPIOIDS
    • NON-NARCOTIC ANALGESICS
  2. MARKET BY INDICATION
    • ARTHRITIC PAIN
    • NEUROPATHIC PAIN
    • CANCER PAIN
    • CHRONIC BACK PAIN
    • POST-OPERATIVE PAIN
    • MIGRAINE
    • FIBROMYALGIA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now